Receiving a diagnosis of prostate cancer after a biopsy can be concerning for many men. However, one of the most important developments in prostate cancer treatment today is that the same treatment is not applied to every patient and unnecessary treatments can be avoided.
One of the first questions many patients ask is:
“I have prostate cancer. Do I need surgery immediately?”
The answer is not always “yes.”
Because some prostate cancers progress very slowly and can be monitored for many years without causing harm to the patient.
This approach is known as Active Surveillance.
Active surveillance is a method of closely monitoring the disease in suitable patients with low-risk prostate cancer instead of immediately performing surgery or radiotherapy.
The aim here is not to refuse or delay treatment.
The aim is to keep the disease under control while avoiding unnecessary treatments.
If the disease shows signs of progression, treatment can be applied at the appropriate time.
No.
Prostate cancers can differ significantly in terms of their biological behavior.
Some tumors:
Others may behave more aggressively and require active treatment.
For this reason, the treatment decision should be made individually.
Many factors are evaluated when deciding on active surveillance.
In general:
are favorable criteria for active surveillance.
However, every patient should be evaluated individually.
Absolutely not.
This is one of the topics most commonly misunderstood by patients.
Active surveillance does not mean “wait and see.”
On the contrary, it requires a planned and regular follow-up program.
During this follow-up, the disease is closely monitored.
Although the follow-up program may vary depending on the patient, it generally includes:
The aim is to detect possible changes in the disease at an early stage.
Yes.
When appropriate patient selection is made, active surveillance is a safe approach accepted in international guidelines today.
Numerous scientific studies have shown that active surveillance provides successful results in suitable patients with low-risk prostate cancer.
The most important point here is not to miss regular follow-up appointments.
Some changes may be detected during follow-up.
For example:
In such cases, active treatments may be considered.
These treatments may include:
This question is frequently asked by patients.
When appropriate patient selection and regular follow-up are performed, active surveillance has not been shown to cause uncontrolled spread of cancer.
The aim is to continuously monitor the disease and intervene in time when necessary.
No.
The treatment decision is not made only according to tumor characteristics.
The patient’s:
should also be taken into account.
While some patients may prefer active surveillance, others may choose to receive treatment.
Receiving a diagnosis of prostate cancer does not always mean that surgery or radiotherapy is required.
In suitable patients, active surveillance is a modern and scientific approach that allows the disease to be monitored safely while avoiding unnecessary treatments.
Many patients with low-risk prostate cancer can be followed for years with a high quality of life.
If you have been diagnosed with prostate cancer, it is important to evaluate all your treatment options in detail with an experienced urology specialist in order to determine the most appropriate approach for you.
Assoc. Prof. Dr. Serdar Yalçın
Urology Specialist
Prostate Cancer • Active Surveillance • MRI Fusion Prostate Biopsy • Robotic Urology • Urologic Oncology
Bu makalenin DoktorTakvimi web sitesinde yayımlanması, yazarın açık izniyle yapılmaktadır. Web sitesindeki tüm içerikler, fikri ve sınai mülkiyet mevzuatı kapsamında uygun şekilde korunmaktadır.
DocPlanner Teknoloji A.Ş. web sitesi tıbbi tavsiye sunmaz. Bu sayfanın içeriği, metinler, grafikler, görseller ve diğer materyaller de dahil olmak üzere, yalnızca bilgilendirme amacıyla oluşturulmuştur ve tıbbi tavsiye, teşhis veya tedavinin yerini almak amacı taşımaz. Herhangi bir sağlık sorununuzla ilgili şüpheniz varsa, bir uzmana danışınız.
15/06/2026
11/06/2026
11/06/2026